Developing Extracellular Protease Inhibitors for Disease Treatment

Daiichi Sankyo, a global pharmaceutical company, is seeking opportunities to collaborate with institutes seeking protease inhibitors for disease treatment. Daiichi Sankyo has in‑house technology to make specific protease inhibitors and would ideally like to work with researchers who have identified proteases involved in mediating diseases, but who have not yet developed an inhibitor for the target protease. 

Approaches of Interest:

• All disease areas that do not currently have protease inhibitor treatment are of interest
• There is a particular interest in targeting diseases of the immune system and inflammatory diseases, but not limited to these
• Projects seeking a targeted inhibitor are preferred, although up to two targets will be considered

Out of Scope:

• Protease inhibitor therapy for viruses such as HIV and hepatitis, infectious diseases and cancer
• Research related to delivery methods of protease inhibitors

Developmental Stages of Interest:

• Daiichi Sankyo is seeking early stage opportunities
• Opportunities should ideally have a disease target, but still seek a protease inhibitor
• In vivo target validation study with a specific protease inhibitor which will be provided by Daiichi Sankyo can be also included in the research collaboration

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. Our client is also open to novel research proposals which can be outlined using this submission form.

Opportunity for Collaboration

Daiichi Sankyo is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.